IDEAS home Printed from https://ideas.repec.org/r/cup/buhirw/v72y1998i02p250-278_07.html
   My bibliography  Save this item

Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Jason Owen-Smith & Massimo Riccaboni & Fabio Pammolli & Walter W. Powell, 2002. "A Comparison of U.S. and European University-Industry Relations in the Life Sciences," Management Science, INFORMS, vol. 48(1), pages 24-43, January.
  2. Dosi Giovanni & Gambardella Alfonso & Grazzi Marco & Orsenigo Luigi, 2008. "Technological Revolutions and the Evolution of Industrial Structures: Assessing the Impact of New Technologies upon the Size and Boundaries of Firms," Capitalism and Society, De Gruyter, vol. 3(1), pages 1-49, June.
  3. Lazonick, William & Tulum, Öner, 2011. "US biopharmaceutical finance and the sustainability of the biotech business model," Research Policy, Elsevier, vol. 40(9), pages 1170-1187.
  4. Krogmann, Yin & Riedel, Nadine & Schwalbe, Ulrich, 2013. "Inter-firm R&D networks in pharmaceutical biotechnology: What determines firm's centrality-based partnering capability," FZID Discussion Papers 75-2013, University of Hohenheim, Center for Research on Innovation and Services (FZID).
  5. Bastian Rake, 2017. "Determinants of pharmaceutical innovation: the role of technological opportunities revisited," Journal of Evolutionary Economics, Springer, vol. 27(4), pages 691-727, September.
  6. Fiedler, Marina & Welpe, Isabell M., 2010. "Antecedents of cooperative commercialisation strategies of nanotechnology firms," Research Policy, Elsevier, vol. 39(3), pages 400-410, April.
  7. Boutillier, Sophie & Laperche, Blandine & Lebert, Didier & Elouaer-Mrizak, Sana, 2023. "A systemic analysis of the technological trajectory at company level based on patent data: The case of Sanofi's vaccine technology," Technovation, Elsevier, vol. 124(C).
  8. Jackie Krafft & Francesco Quatraro & Pier Saviotti, 2014. "Knowledge characteristics and the dynamics of technological alliances in pharmaceuticals: empirical evidence from Europe, US and Japan," Journal of Evolutionary Economics, Springer, vol. 24(3), pages 587-622, July.
  9. Konstantinos Grigoriou & Frank T. Rothaermel, 2017. "Organizing for knowledge generation: internal knowledge networks and the contingent effect of external knowledge sourcing," Strategic Management Journal, Wiley Blackwell, vol. 38(2), pages 395-414, February.
  10. Martin Backfisch, 2018. "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics 201813, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
  11. Chi-Yen Yin & Hsiao-Hsin Chang, 2022. "What Is the Link between Strategic Innovation and Organizational Sustainability? Historical Review and Bibliometric Analytics," Sustainability, MDPI, vol. 14(11), pages 1-23, June.
  12. Fabio Pammolli & Massimo Riccaboni & Alessandro Spelta, 2021. "The network origins of Schumpeterian innovation," Journal of Evolutionary Economics, Springer, vol. 31(5), pages 1411-1431, November.
  13. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
  14. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
  15. Frank T. Rothaermel & Andrew M. Hess, 2007. "Building Dynamic Capabilities: Innovation Driven by Individual-, Firm-, and Network-Level Effects," Organization Science, INFORMS, vol. 18(6), pages 898-921, December.
  16. Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
  17. Rothaermel, Frank T. & Thursby, Marie, 2007. "The nanotech versus the biotech revolution: Sources of productivity in incumbent firm research," Research Policy, Elsevier, vol. 36(6), pages 832-849, July.
  18. Chataway, Joanna & Hanlin, Rebecca & Mugwagwa, Julius & Muraguri, Lois, 2010. "Global health social technologies: Reflections on evolving theories and landscapes," Research Policy, Elsevier, vol. 39(10), pages 1277-1288, December.
  19. Wei Teng, Chih & Foley, Lucy & O'Neill, Peter & Hicks, Chris, 2014. "An analysis of supply chain strategies in the regenerative medicine industry—Implications for future development," International Journal of Production Economics, Elsevier, vol. 149(C), pages 211-225.
  20. Hopkins, Michael M. & Martin, Paul A. & Nightingale, Paul & Kraft, Alison & Mahdi, Surya, 2007. "The myth of the biotech revolution: An assessment of technological, clinical and organisational change," Research Policy, Elsevier, vol. 36(4), pages 566-589, May.
  21. Roijakkers, Nadine & Hagedoorn, John & van Kranenburg, Hans, 2005. "Dual market structures and the likelihood of repeated ties - evidence from pharmaceutical biotechnology," Research Policy, Elsevier, vol. 34(2), pages 235-245, March.
  22. Roijakkers, Nadine & Hagedoorn, John, 2006. "Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks," Research Policy, Elsevier, vol. 35(3), pages 431-446, April.
  23. Jean-François Hennart, 2020. "More than intent: A bundling model of MNE–SME interactions," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 51(7), pages 1176-1194, September.
  24. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
  25. Krogmann, Yin & Schwalbe, Ulrich, 2011. "Inter-firm R&D networks in the global pharmaceutical biotechnology industry during 1985 - 1998: A conceptual and empirical analysis," FZID Discussion Papers 38-2011, University of Hohenheim, Center for Research on Innovation and Services (FZID).
  26. Achilladelis, Basil & Antonakis, Nicholas, 2001. "The dynamics of technological innovation: the case of the pharmaceutical industry," Research Policy, Elsevier, vol. 30(4), pages 535-588, April.
  27. Srikanth Paruchuri & Atul Nerkar & Donald C. Hambrick, 2006. "Acquisition Integration and Productivity Losses in the Technical Core: Disruption of Inventors in Acquired Companies," Organization Science, INFORMS, vol. 17(5), pages 545-562, October.
  28. Claus Rerup, 2009. "Attentional Triangulation: Learning from Unexpected Rare Crises," Organization Science, INFORMS, vol. 20(5), pages 876-893, October.
  29. Kneller, Robert, 2003. "Autarkic drug discovery in Japanese pharmaceutical companies: insights into national differences in industrial innovation," Research Policy, Elsevier, vol. 32(10), pages 1805-1827, December.
  30. Daniel F. Spulber, 2013. "How Do Competitive Pressures Affect Incentives to Innovate When There Is a Market for Inventions?," Journal of Political Economy, University of Chicago Press, vol. 121(6), pages 1007-1054.
  31. Franco Malerba & Luigi Orsenigo, 2000. "Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening," KITeS Working Papers 124, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Jan 2001.
  32. Eric Jolivet & Caroline Lanciano-Morandat & Hiroatsu Nohara & Daniel Pardo, 2009. "Biopharmaceutical entrepreneurship in two Japanese and French bioclusters: differences in founder profiles and experience," Post-Print halshs-00424901, HAL.
  33. Moritz Müller & Robin COWAN & Geert Duysters & Nicolas JONARD, 2009. "Knowledge Structures," Working Papers of BETA 2009-24, Bureau d'Economie Théorique et Appliquée, UDS, Strasbourg.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.